Skip to main content
Create Account
About PLI PLUS
Help
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Treatises
Forms
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Developments in Pharmaceutical and Biotech Patent Law 2019
Chair(s):
David K. Barr
Practice Area:
Intellectual Property
Published:
Oct 2019
ISBN:
9781402434921
PLI Item #:
252834
CHB Spine #:
G1436
This version is not current.
Click here for the most recent version.
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. Excerpt from Ch. 5: Patentability, Practising Law Institute, Pharmaceutical and Biotech Patent Law § 5:8 (March 2019)
Chapter 2. Blocking Patents and the Proper Role of Objective Indicia in Determining Nonobviousness
Chapter 3. Post-TC Heartland Venue Issues in Hatch-Waxman Cases and the Printed Matter Doctrine
Chapter 4. Patent Due Diligence in Pharmaceutical and Biotech Patent Transactions
Chapter 5. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015)
Chapter 6. Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, 887 F.3d 1117 (Fed. Cir. 2018)
Chapter 7. Berkheimer v. HP Inc., 890 F.3d 1369 (Fed. Cir. 2018)
Chapter 8. Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC, 2019 WL 2847219 (Fed. Cir. July 3, 2019)
Chapter 9. Rapid Litigation Management Ltd. v. CellzDirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016)
Chapter 10. 2019 Revised Patent Subject Matter Eligibility Guidance, Federal Register, Vol. 84, No. 4 (January 7, 2019)
Chapter 11. U.S. Senators Chris Coons (D-Del.) and Thom Tillis (R-N.C.), and Representatives Doug Collins (R-Ga.), Hank Johnson (D-Ga.) and Steve Stivers (R-Ohio), Section 101 Patent Reform Framework and Draft Bill (April–May 2019)
Chapter 12. Post-Grant Proceedings in Life Sciences: Strategic Patent Considerations
Chapter 13. Supplemental Materials for Post-Grant Proceedings in Life Sciences: Strategic Patent Considerations
Chapter 14. Sanjay K. Murthy, Michael T. Sikora and Christopher J. Hall, Ethical Issues Confronting Life Sciences Patent Lawyers
Index
About Us
